[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meningitis-viral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meningitis-viral":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100626167","prediction-of-infectious-agents-in-the-biofire-filmarray-biomrieux-meningitisencephalitis-panel-based-on-clinical-syndrome-and-cerebrospinal-fluid-parameters-a-diagnostic-stewardship-proposal-100626167",false,"NCT07432113","Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis\u002FEncephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal.","Inclusion Criteria:\n\nPatients aged 18 years or older, of any gender.\n\nPresence of at least two of the following symptoms: fever, lethargy, altered level of consciousness, seizures, acute focal deficit, signs of meningeal irritation, or headache.\n\nSymptoms must have started within the last 30 days.\n\nObligatory presence of pleocytosis (CSF white blood cell count ≥ 5 cells\u002Fmm³).\n\nProvision of written Informed Consent (TCLE) by the patient or their legal representative.\n\nExclusion Criteria:\n\n* Failure to sign the Informed Consent Form.\n\nClinical manifestations lasting more than 30 days.\n\nPatients under 18 years of age.\n\nPatients who have undergone neurosurgery within 30 days prior to the onset of symptoms (applies to both prospective and control groups).","ALL","18 Years",{"count":18,"type":19},182,"ESTIMATED","INTERVENTIONAL",[22],"NA","Background: Infections of the central nervous system (CNS) are associated with high morbidity, mortality, and high resource consumption. The BioFire FilmArray is a molecular diagnostic panel capable of identifying 14 pathogens in approximately one hour, including bacteria, viruses, and fungi. However, it is not yet widely available in the Brazilian public health system.\n\nObjective: The primary objective of this study is to evaluate the pre-test probability of positivity of the Biofire FilmArray bioMérieux Meningitis\u002FEncephalitis panel in patients with clinical syndrome of meningitis and\u002For encephalitis and pleocytosis (CSF ≥ 5 cells).\n\nAs secondary objectives, the study aims to:\n\nDetermine the clinical impact of using the panel through variables such as total hospital stay and length of stay in the intensive care unit.\n\nCompare the duration of antibiotic use in non-bacterial cases between groups. Compare the time to reduction of acyclovir use in etiologies without proven benefit.\n\nCompare the time for identification of the causative pathogen and mortality rates between the study groups.\n\nPerform a cost-effectiveness analysis of the test. Compare the request for imaging exams, such as brain MRI and CT scan, between the groups.\n\nMethods: This is a prospective, transversal, and multicenter study conducted at Santa Casa de Porto Alegre and Hospital Dom João Becker. Patients will be compared with a retrospective cohort used as a control group.",[25,26,27,28,29,30],"Meningitis","Encephalitic Infection","Encephalitis","Meningitis, Fungal","Meningitis, Viral","Meningitis, Bacterial",[32,33,34,35,36],"filmarray","biofire","biofire filmarray","meningits","encephalitis","NOT_YET_RECRUITING","2026-02-18",{"date":40,"type":41},"2026-02-25","ACTUAL",{"date":43,"type":19},"2026-03-16",{"date":45,"type":19},"2029-10-31",{"name":47,"class":48},"Federal University of Health Science of Porto Alegre","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":20,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100474056","phase-4-aciclovir-versus-placebo-for-hsv-2-meningitis-100474056","NCT05452928","Aciclovir Versus Placebo for HSV-2 Meningitis","Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)","AMEN","Inclusion Criteria:\n\n* Adults ≥18 years of age admitted on suspicion of viral meningitis defined as:\n\n  1. A clinical presentation consistent with viral meningitis (e.g. headache, nuchal rigidity, photophobia, or fever) AND\n  2. Cerebrospinal fluid (CSF) pleocytosis (\\>4 leukocytes x 106\u002FL) AND\n  3. HSV-2 positive by PCR of the CSF\n  4. Glasgow Coma Scale score of 15 AND\n  5. Ability to absorb oral medications\n\nExclusion Criteria:\n\n* Patients fulfilling any of the following criteria will be excluded:\n\n  1. Encephalitis as defined by the International Encephalitis Consortium if diagnosed during standard care (see Glossary)20\n  2. Transverse myelitis as defined by the Transverse Myelitis Consortium Working Group if diagnosed during standard care (see Glossary)21\n  3. Severe immuno-compromise defined as an ongoing need for biological- or chemotherapy (e.g. natalizumab), prednisolone \\>20 mg\u002Fday for ≥14 days, uncontrolled HIV\u002FAIDS (see glossary), haematological malignancies, and organ transplant recipients14,18,22\n  4. Moderate to severe concomitant genital herpes requiring systemic aciclovir\n  5. Pregnancy (proven by positive urine or plasma human chorionic gonadotropin test in fertile women)\n  6. Hepatic impairment (aspartate aminotransferase or alanine aminotransferase levels \\>5 times the upper limit of normal)\n  7. Impaired renal function (estimated glomerular filtration rate \\\u003C25 mL\u002Fmin)\n  8. Intolerance to (val)aciclovir\n  9. Probenecid treatment\n  10. Systemic antiviral therapy with an antiherpetic effect for \\>24 hours\n  11. Previous enrolment into this trial",true,{"count":60,"type":19},150,[62],"PHASE4","To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation",[65,29],"Herpes Simplex 2",[67,68,69,70,71,72,73,74,75],"meningitis","HSV-2","Herpes simplex 2","viral meningitis","aseptic meningitis","acyclovir","valacyclovir","aciclovir","valaciclovir","2025-09-30",{"date":78,"type":41},"2025-10-01",{"date":80,"type":19},"2026-06-01",{"date":82,"type":19},"2029-06-01",{"name":84,"class":48},"Jacob Bodilsen"]